Long-term safety and tolerability of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis: Pooled safety analysis of three phase 3, randomized controlled trials

Authors
Category Primary study
ConferenceScandinavian Journal of Rheumatology
Year 2014
This article has no abstract
Epistemonikos ID: 61f88822e77c0f965cefefe0a27fbea9b3b2bfaf
First added on: Apr 30, 2026